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Abstract
Uremic syndrome results from malfunctioning of various organ systems due to the retention of uremic toxins which, under
normal conditions, would be excreted into the urine and/or metabolized by the kidneys. The aim of this study was to
elucidate the mechanisms underlying the renal elimination of uremic toxin creatinine that accumulate in chronic renal
failure. Quantitative investigation of the plausible correlations was performed by spectroscopy, calorimetry, molecular
docking and accessibility of surface area. Alkalinization of normal plasma from pH 7.0 to 9.0 modifies the distribution of
toxin in the body and therefore may affect both the accumulation and the rate of toxin elimination. The ligand loading of
HSA with uremic toxin predicts several key side chain interactions of site I that presumably have the potential to impact the
specificity and impaired drug binding. These findings provide useful information for elucidating the complicated
mechanism of toxin disposition in renal disease state.
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Introduction
The uremic syndrome is attributed to the progressive retention
of a large number of biologically/biochemically active endogenous
solutes called ‘‘uremic toxins’’, which under normal conditions are
excreted by the healthy kidneys [1,2]. The accumulation of these
human metabolic products in blood has been implicated in a
number of toxic effects in uremic patients, including cardio-
vascular damage, progressive loss of glomerular filtration, bleeding
tendencies from platelet dysfunction, hypertension, neuropathy,
irregularities in thyroid function, and defective protein binding of
medicinal preparations [3–5].
Among the highly increased uremic guanidino compounds
(GCs), creatinine (CTN; 2-Amino-1-methyl-5H-imidazol-4-one,
C4H7N3O), is the most typical example of small water-soluble
breakdown waste product generated from muscle metabolism
which can easily be removed by any dialysis strategy [6,7]. CTN
have been used as a conventional biomarker that predicts several
important health outcomes, to diagnose acute kidney injury
involving the measurement of levels of serum creatinine, blood
urea nitrogen, and urinary enzymes, all of which are elevated after
substantial kidney function is lost [8]. Its concentration for a
healthy person is in the range of 35–106 mM whereas for a person
with uremia reaches upto mM [6]. The normal level of albumin-to-
creatinine ratio (ACR) in blood depends highly on sex, body
muscle mass, age, racial/ethnic groups [9] and diseased states.
ACR predicts several health outcomes such as neurotoxicity [10],
hypertension [11,12], and vascular damage due to leukocyte
activation [13], kidney failure [14], cardiovascular events, [15] and
microalbuminuria [16]. In renal diseases, the pharmacokinetics of
many drugs are altered even when the primary route of
elimination is not renal, due to changes in protein binding,
volume of distribution, and/or acid-base disturbance [17].
We elucidate the interaction of CTN during the pH dependent
structural transition, often referred to as the Neutral (N) – Basic (B)
transition [18,19] of Human serum albumin (HSA) which
regulates the volume of circulating plasma; therefore, albumin
must be conserved by the body [20]. The structural transitions and
toxin binding properties were evaluated by means of calorimetric
and, spectroscopic approaches using typical site-specific bound
drugs (warfarin, phenylbutazone, ibuprofen and diazepam). The
competitive binding of a toxin affects the transport of endogenous
as well as exogenous substances especially site specific drugs
targeted to the focus of disease for therapeutic effect [20]. The
elimination of such toxins from the blood stream of patients
suffering from chronic renal failure which was an important
therapeutic goal was found to be dependent on albumin con-
formation. We determine the high affinity binding site of CTN on
HSA using displacement, molecular docking and surface accessi-
bility. The major amino acid residue being involved in the
interaction was Arg257 which provides the guanidino group to the
toxin. The primary binding site of toxin was located in the vicinity
of Arg257 or near to loop 4 and 6 in subdomain IIA which
corresponds approximately to amino acid position of 190–300,
one of the two principal sites on HSA for small ligands [20]. Thus,
binding of CTN to its high affinity (site I) and low affinity (site II)
PLoS ONE | www.plosone.org 1 February 2011 | Volume 6 | Issue 2 | e17230sites indirectly displaces drugs from albumin and increases the
transiently liberated toxin molecules leading to impaired drug
binding.
Materials and Methods
Materials
Human serum albumin (lot No. A1887; essentially fatty acid
free and globulin), creatinine (lot No. C4255), warfarin (lot No.
A2250), ibuprofen (lot No. I4883) and phenylbutazone (lot No.
P8386) were purchased from Sigma. Diazepam was a product
from Ranbaxy Laboratories Ltd., India. All of the other reagents
were of analytical grade.
Preparation of HSA Isomers and creatinine solutions
The protein and toxin solutions were prepared in pH 7.0
(60 mM sodium phosphate) and pH 9.0 (10 mM glycine-NaOH)
buffer solutions. The protein concentration used was similar to
that of albumin concentration present in blood i.e. 500 mM and
was determined spectrophotometrically using E1%
1cm of 5.31 [21] at
279 nm on a Hitachi spectrophotometer, model U-1500. The
concentration of creatinine (Mw=113.12) used varies accordingly
from normal serum creatinine (106 mM) to uremic conditions
(2000 mM) as previously analyzed in a survey of patients suffering
from uremic disorders [6]. For all measurements we have used
three form of protein preparations as ‘free HSA’ not complexed
with toxin; ‘normal condition’ describes the solution of HSA
complexed with minimal craetinine concentration and ‘uHSA’
describes the term used for the protein/toxin complex responsible
for maximal uremic conditions. In all of these preparations, we
have used HSA/CTN ratio similar to that of in-vivo conditions i.e.
ACR=5 (normal condition) and ACR=0.25 (maximal uremic
condition).
Differential Scanning Calorimetry (DSC)
The thermal denaturation of the proteins was carried out on a
VP-DSC microcalorimeter (MicroCal Inc., Northampton, MA).
The thermograms were obtained in the temperature range of 30–
90uC at a scanning rate of 0.5 K/min. Before being loaded into
the cells, the sample (HSA or HSA-CTN) and the reference (buffer
or buffer-CTN) solutions were degassed by stirring in an evacuated
chamber at room temperature. The solution with the vial was
weighed before and after degassing, and the appropriate amount
of degassed deionized water was added to make up for any loss of
water thus evaporated. The solutions were then immediately
loaded into the respective cells. The calorimetric reversibility of
the thermal transitions was determined by heating the sample to a
temperature that was a little over the transition maximum, cooling
immediately, and then reheating. The reversible non-two-state
denaturation model provides the temperature where the area
under the transition curve is half complete (DTm), van’t Hoff
(DHVH) and calorimetric (DHm) enthalpies depicting actual heat
absorption during protein unfolding. The cooperative unit is
defined by the ratio DHm/DHvH [22].
Isothermal Titration Calorimetry (ITC)
The energetic of the binding of creatinine to HSA were
measured using a VP-ITC titration microcalorimeter (MicroCal
Inc., Northampton, MA). All the solutions were thoroughly
degassed before loading, and the consequent water loss was
compensated using degassed deionized water. The reactant
(500 mM protein solution) was placed in the sample cell (1.4 ml)
and the injectant (2000 mM creatinine solution) was introduced
into the calorimeter in 8 ml increments spaced 400 sec apart. The
injection syringe rotated at a speed of 300 rpm throughout the
experiment to facilitate mixing of the reaction components.
Sequential titrations were performed to ensure full occupancy of
the binding sites by loading and titrating with the same ligand
without removing the samples from the cell until the titration
signal was essentially constant. To correct for the dilution effect by
the injection of toxin solution, two controls were obtained: titration
of HSA solution by the buffer to account for HSA dilution and
titration of buffer solution by creatinine solution to account for
toxin dilution effect. Experiments were repeated two or more times
to get a reproducibility of better than 3%. The generated were
integrated using the single set of identical binding sites model of
Origin 7 software provided by MicroCal. The experimental data
were best fitted to a binding model depending upon the least chi-
square values obtained. The enthalpy change for each injection
was calculated by integrating the area under the peaks of the
recorded time course of change of power and then subtracted with
the control titrations. The other thermodynamic parameters were
calculated according to the formulas [23,24]:
DG~{RTlnKa~DH{TDS......... ðiÞ
Where T is the absolute temperature (298K) and R=8.3151 J
mol
21 K
21.
Fluorescence Measurements
The intrinsic fluorescence properties of the protein were studied
on a Hitachi spectrophotometer, model F-4500. The fluorescence
spectra were measured at 2560.1uC with a 1 cm path length cell.
The excitation and emission slits were set at 10 and 20 nm,
respectively. Intrinsic fluorescence was measured by exciting the
protein solution at 280 and 295 nm to selectively excite the
chromophoric molecules, and the emission spectra were moni-
tored in the wavelength range 300–500 nm. The emission spectra
of the protein-toxin solutions were subtracted from the buffer-
toxin blanks, and an average of three accumulated scans was
recorded as the final graph. The fluorescence data were analyzed
according to linear and modified stern-volmer equations as
[21,25]:
Fo=F~1zKsv Q   ......... ðiiÞ ½ ½
log Fo{F ðÞ =F
hi
~logKznlog Q   ......... ðiiiÞ ½ ½
FT-IR Spectroscopic Measurements
Infrared spectra were recorded on a Nicolet Magna 750 FT-IR
spectrophotometer (DTGS detector, Ni-chrome source and KBr
beamsplitter) with a total of 100 scans and resolution of 16 cm
21,
using AgBr windows at room temperature. The concentration of
HSA was 500 mM. The difference spectra [(protein solution) -
(protein solution + ligand solution)] were collected after 1 h of
incubation of HSA. The protein FT-IR spectra were processed as
the procedures as reported by Kang et al. [26].
Determination of the Protein Secondary Structure
The secondary structure content of HSA and the HSA
complexed with toxin under normal and maximal uremic
conditions was determined from the shape of the amide I band,
located around 1650–1660 cm
21. The FT-IR spectra were
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the built-in software of the spectrophotometer (OMNIC version
3.1). Each Lorentzian band was assigned to a secondary structure
according to the frequency of its maximum; a-helix (1656–
1658 cm
21), b-sheet (1614–1638 cm
21), turn (1660–1677 cm
21),
random coil (1640–1648 cm
21), and b-antiparallel (1680–
1692 cm
21) were adjusted and the area was measured with the
Gaussian function. The relative percentage of the secondary
structural elements was obtained from the area under the
Gaussian curve [27].
CD and UV spectroscopic Measurements
CD and UV spectra were recorded on a Jasco J-815
spectropolarimeter, equipped at 2560.2uC in a rectangular
cuvette with 1 cm pathlength under a constant nitrogen flow.
Each spectrum was signal-averaged at least two times with a
bandwidth of 1.0 nm and resolution of 0.2 nm, at a scan speed of
20 nm/min. Temperature control was provided by a Peltier
thermostat equipped with magnetic stirring. Stock solutions of the
site specific markers 6.8610
3 mM warfarin, 6.8610
3 mM phenyl-
butazone, 1.2610
4 mM ibuprofen, 8610
3 mM diazepam were
prepared and added stepwise in ml volumes to the creatinine–HSA
solutions both at pH 7.0 and 9.0. These solutions were prepared
by dissolving in ethanol such as its concentration never exceeded
13% and the effects of the organic solvent on the CD
measurements were undetectable. Induced CD spectra resulting
from the interaction of the toxin with HSA were obtained by
subtracting the CD spectrum of the protein from that of the
protein-toxin complex. Ellipticities values were converted to ‘De’
values using the equation De=h/(33982cl) where, De is the molar
Figure 1. Differential scanning calorimetry of HSA in absence and presence of creatinine. Melting thermograms of Human Serum
Albumin under normal (A and B) and uremic (C and D) conditions at pH 7.0 (A and C) and pH 9.0 (B and D).
doi:10.1371/journal.pone.0017230.g001
Table 1. Thermodynamic parameters accompanying thermal
unfolding of HSA complexes with creatinine at a scan rate of
0.5 K/min.
Condition Tm [K] DHm [Kcal/mol]
T1
m
a T2
m
a DH1
m
b DH2
m
b
A 59.8460.63 64.5960.28 14.260.52 35.260.54
B 61.0160.51 65.8360.35 26.260.38 13.260.38
C 59.9360.02 80.2760.05 143.0060.52 39.3160.09
D 65.0660.12 80.3160.07 110.3060.96 58.6960.15
Condition A: N Isomer of HSA at pH 7.0.
Condition B: B Isomer of HSA at pH 9.0.
Condition C: N Isomer of HSA at pH 7.0+ CTN.
Condition D: B Isomer of HSA at pH 9.0+ CTN.
aMidpoint of thermal denaturation.
bCalorimetric enthalpy.
Superscripts 1 and 2 refer to the low and high unfolding transition, respectively
(see text for details).
doi:10.1371/journal.pone.0017230.t001
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albumin at pH 7.0 (A) and 9.0(B) respectively were performed at 25uC. In the top panels, the heat released per unit time (mcal/sec) was plotted vs time
where each peak corresponds to the injection of an aliquot of ligand. In the bottom panels, the heat of reaction per injection (kcal/mole) was
determined by integration of the area under each peak, plotted vs [CTN]/[HSA], and fit using the software provided by Microcal. (C) Comparative
distribution of DH, TDS and DG at pH 7.0 (dark grey) and pH 9.0 (light grey).
doi:10.1371/journal.pone.0017230.g002
Table 2. Association constants and thermodynamic data for binding of creatinine to HSA.
Condition Ka[M
21]n
DGa
[Kcal/mol]
DHa
[Kcal/mol]
DSa
[cal/mol/K]
ITC
a Spec
b ITC
a Spec
b
A 8.92610
4* 1.15610
4
#2.92610
4
0.98
*0.94
#1.07
26.75 20.01760.91 22.6
B 2.69610
5* 9.76610
5
#1.36610
5
0.94
*1.29
#1.17
223.03 215.5360.79 225.2
Condition A: N Isomer of HSA at pH 7.0+ CTN.
Condition B: B Isomer of HSA at pH 9.0+ CTN.
aConstants determined by Isothermal Titration Calorimetry.
bConstants determined by Fluorescence spectroscopy (
*lexcitation=280 nm;
#lexcitation=295 nm).
doi:10.1371/journal.pone.0017230.t002
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21cm
21,ci s
the concentration of the sample expressed in mol/L, and l is the
pathlength through the cell expressed in cm.
Molecular Docking Studies
The crystal structure of HSA site I markers (warfarin, PDB ID:
1H9Z; phenylbutazone, PDB ID: 2BXC) and the site II markers
(diazepam, PDB ID: 2BXF; ibuprofen, PDB ID: 2BXG) were
derived from Protein Data Bank. The residues falling within 5 A ˚
distance of the marker were extracted and combined to define the
binding site. The two dimensional (2D) structures of ligands were
extracted from Pubchem database in SDF (Structure Data File)
format. The three dimensional structures were generated with
CORINA version 2.6 [28]. Molecular docking simulations of
uremic toxin and site specific probes were carried out using the
GOLD version 3.1.4 program (Genetic Optimization Ligand
Docking) [29] software which uses a genetic algorithm to
calculate the possible conformations of the toxin that binds to
the protein. The ligands were docked to active site of HSA using
standard set parameters of GOLD throughout the simulations.
For each of the 100 independent genetic algorithm runs, a
selection pressure of operations were set to terminate after a
maximum of 2,500,000 energy evaluations. Lowest energy
complex geometries and the corresponding free energy of binding
were calculated. Top 20 poses were saved for each ligand and
best score values were used to correlate with experimental data.
The binding energies of docked molecules were also calculated
using X-score [30]. The hydrogen bonding (cutoff distance of
2.8–3.2 A ˚ between donor and acceptor) and hydrophobic
interactions between ligand and protein were calculated using
Getneares, a program available with DOCK version 3.1.4 [31].
PyMol version 0.99 [32] and chimera version 1.3 [33] were used
for visualization and measurement of distances between the
ligand and the receptor.
The Accessible Surface Area (ASA) of uncomplexed HSA and
complexes of ligands with HSA were calculated using NACCESS
version 2.1.1 [34]. The structure of the ligands corresponding to
the final docked conformation was chosen and composite
coordinates were generated to form the docked complex. The
change in ASA (DASA) of the i
th residue was calculated using the
expression:
DASAi~ASA
HSA
i {ASA
HSA-Ligand
i ......... ðivÞ
If a residue lost more than 10 A ˚ 2 ASA on going from the
uncomplexed to the complexed state, it was considered as being
involved in interaction [35].
Figure 3. Fourier transform infrared (FTIR) measurements of HSA in absence and presence of creatinine. Infrared spectra were recorded
on a FTIR spectrometer in the region 1800–1400 cm
21 at pH 7.0 (A) and pH 9.0 (B) for the free HSA, free CTN and difference spectra of HSA-CTN
complexes (bottom two curves) obtained under normal serum (ACR=5) to uremic condition (ACR=0.25) (indicated in the figure).
doi:10.1371/journal.pone.0017230.g003
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Thermal Denaturation of N and B isomer of HSA in
presence of creatinine
The representative differential scanning calorimetric profiles of
thermal denaturation of N and B isomers of HSA in absence and
presence of creatinine were performed under normal and uremic
condition as shown in Figure 1 (for simplicity we have only shown
data for native protein at pH 7.0 (A) pH 9.0 (B) and maximal
uremic conditions at pH 7.0 (C) and 9.0 (D) respectively. The
corresponding thermodynamic parameters accompanying the
transitions were reported in Table 1. In the absence of toxin, N
isomer of HSA unfolds with reversible endotherm at transition
temperatures of 59–64uC and an average calorimetric enthalpy of
14.2–35.2 kcal/mol. Almost similar value of the transition temper-
ature of N and B isomeric forms (in absence of toxin) indicates the
extent of the binding interactions of positive charge of amino acid
residues participating in the molecular mechanism of this
equilibrium. However, a little difference in the cooperativity ratio
b was found to be 1.0260.01 (data not shown), indicating that the
thermal unfolding of the protein in the presence of toxin even at
higher concentrations was a reversible process. These values were in
concurrence with those reported in the literature [36]. The melting
curve of uremic plasma (albumin complexed with creatinine) shows
a different shape without any reversal in amplitude of the two peaks
but a slight shift to the right at higher temperature. The toxin
renders the strongest influence on the endotherms (more pronounce
for basic isomer of HSA, Figure 1D) by transforming the unimodal
curve of its melting to a bimodal one. As it follows from Figure 1, on
reaching from normal to maximal uremic condition, the melting
curve was practically identical to that for the complex ‘‘albumin-
nonconjugated bilirubin’’ [37].
Isothermal Titration Calorimetry of N and B isomer of
HSA in presence of creatinine
In order to determine thermodynamic parameters for binding
we performed isothermal titration calorimetry of creatinine with
Figure 4. Determination of protein secondary structure complexed with creatinine. Curve fitted amide I region (1700–1600 cm
21) with
secondary structure determination of the free HSA and its toxin adducts in aqueous solution with varying ACR molar ratios and 500 mM protein
concentrations at pH 7.0 (A) and pH 9.0 (B).
doi:10.1371/journal.pone.0017230.g004
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titration profile of ACR at molar ratio of 1:4 (HSA in normal
serum: HSA complexed with creatinine under uremic conditions)
at pH 7.0 (A) and pH 9.0 (B) were shown in Figure 2. Each peak
in the binding isotherms (Figure 2, upper panels) represents a
single injection of creatinine. The negative deflections from the
baseline on addition of creatinine indicate that heat was evolved
(an exothermic process). The enthalpy change associated with
each injection of ligand was plotted versus the [CTN]/[HSA]
molar ratio (Figure 2, lower panel), and the DH, Ka, the free
energy change (DG) associated with binding were determined from
the plots. The thermodynamic data derived from the model fitting
were summarized in Table 1. The 1:4 binding stoichiometry of
CTN to basic isomer of HSA with a binding constant of
2.69610
5 M
21 indicates a strong and specific interaction. This
binding constant was of larger order of magnitude than that of
neutral form (8.92610
4 M
21) as shown in Table 2. Furthermore,
the heat released during the CTN-HSA reaction increases with
increasing pH, i.e., the ion pair attraction and H-bonds between
CTN and HSA were weakened. This indicates that the number of
H-bonds formed by CTN was lower at pH 7.0. In contrast, DS
become more negative with increasing pH. This indicates that
CTN binding destroyed the internal hydrophobic interactions in
HSA at pH 9.0, replacing them with ion pair attraction and H-
bonds. Comparison of the DG, DH, and TDS values suggests that
the CTN-HSA interaction was amphipathic and H-bonds and ion
pair binding were both major contributors, i.e., the interaction of
CTN with HSA depends on a combination of ion pair attraction
and H-bonds (Figure 2C).
Analysis of secondary structure of N and B isomer of HSA
in presence of creatinine
To investigate the effects of the uremic toxin creatinine on the
secondary structure of albumin, we analyzed regions of IR spectra
caused by vibrations of polypeptide backbone, viz., the amide I
(1700–1600 cm
21, mainly C=O stretch) band and the amide II
(1500–1600 cm
21, C-N stretching coupled with N-H bending
modes) band. The amide I band of free HSA (Figure 3) had a
major maximum around 1654 cm
21 for native and 1657 cm
21 for
basic isomer, characteristic of the a-helical conformation [34].
Similarly, the infrared self-deconvulation and curve fitting
procedures were used to determine the protein secondary structure
under normal and uremic conditions both at pH 7.0 and 9.0
(Figure 4, Table 3).
Positions and relative intensities of the components in presence
of toxin (i.e. uremic condition) did not differ significantly from
those of normal HSA (free HSA without toxin). Though
quantitative analysis of the amide I (Table 3) revealed a substantial
decrease in the amount of a-helical conformation and an increase
in b-sheets and or/extended chains in uremic HSA. The decrease
in the intensity of amide I and amide II bands, mainly C=O and
C-N vibrations, compared to low toxin concentration (normal
condition) suggests major protein conformational changes upon
HSA-toxin interaction possibly caused by a reorganization of
intra- and intermolecular hydrogen bonding. The toxin-HSA
complexation suggests partial protein unfolding more pronounced
at higher molar ratio (uremic condition) i.e. similar to uremic
diseased state and for basic isomeric form of HSA. The IR spectra
of uremic HSA (HSA complexed with toxin) at higher molar ratios
for both isomers showed appearance of some new components for
amide II band (Figure 3). This band was caused by vibrations of
the peptide N-H groups and by motions of Glu, Asp, Tyr, Lys and
His side chains. We observed main alterations in the range 1652–
1695 cm
21 that were basically associated with that of Arg
environment. Because the appearance of this component in the
IR spectra of uHSA was accompanied by no changes in the
peptide C=O absorption, it likely reflects alterations in the
environment of Glu and Asp side chains in uHSA molecules
[38].
Fluorescence spectroscopy of N and B isomer of HSA in
presence of creatinine
Both the intensity and the position of the fluorescence emission
spectrum of tryptophan were sensitive to changes in the
fluorescence environment and consequently to the protein
conformation. Hence, to understand the influence of creatinine
binding on the neutral and basic form of HSA we studied the
changes in the intrinsic fluorescence of the protein. Figure 5 shows
the fluorescence spectra of HSA in the presence of increasing
concentration of creatinine. The fluorescence quenching data
were analyzed according to the Linear (Figure 5A and C) and
modified Stern-Volmer equation (Figure 5B and D) [21,35] after
Table 3. FT-IR/ATR determination of secondary structure percentages of N and B isomers of HSA and its uremic complexes.
Amide I components N isomer B isomer
Free HSA
(%)
Normal
a
(%)
Uremic
b
(%)
Free HSA
(%)
Normal
a
(%)
Uremic
b
(%)
b-antiparallel
(1675–1695 cm
21)
8621 5 611 0 611 0 621 2 621 2 61
Turns
(1666–1673 cm
21)
15611 8 611 5 611 5 622 0 611 0 62
a-helix
(1650–1658 cm
21)
54624 5 615 0 625 3 614 2 624 3 62
Random coil
(1637–1645 cm
21)
6611 2 618 611 5 621 9 622 5 61
b-sheets
(1613–1625 cm
21)
17611 0 611 7 617 628 621 0 62
aNormal condition: HSA complexed with creatinine under normal serum condition.
bUremic condition: HSA complexed with creatinine under maximal uremic condition.
These complexes were obtained incubating uremic toxin with 500 mM of HSA for 1 hr at room temperature. Data represent average obtained from two independent
replicates, standard error is indicated.
doi:10.1371/journal.pone.0017230.t003
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quenching of albumin fluorescence was not affecting the binding
strength of tryptophan fluorescence. This may be so because
binding of uremic toxin was not exactly at the site where
tryptophan resides but it could be somewhere near to it as it
mainly affects tyrosine fluorescence. These results are comparable
with that of our ITC results and are presented in Table 2 further
confirming that association constant Ka of uremic toxin depends
on conformation of HSA underwent N-B transitions.
Dependence on alkalization of the Optical properties of
creatinine-HSA solution
The conjugated double bond system of creatinine constitutes the
light absorbing chromophore that has no element of chirality; it
does not show CD activity. The toxin gives the weak absorption
band associated with an electronic dipole allowed L-L* transition
which becomes optically active upon binding to the asymmetric
environment of HSA and an induced CD spectrum emerges a
weak positive L-L* CD band between 250–350 nm (Figure 6).
Regarding the interaction of toxin with the albumin binding site, it
has to be noted that dissociated ligand molecules lose their
hydrogen donor properties but at the same time, they become
more powerful proton acceptors ready to form H bonds with basic
residues of HSA. Upon increasing pH value, the CD signals and
absorption curves of HSA-CTN complex enhances; triggered by
the protonation of histidine residues, toxin flips away at neutral
and alkaline pH values and the cavity becomes accessible for the
ligand molecule. The spectra obtained by toxin titration
experiment (Figure 6A) clearly demonstrate that the protein
microenvironment at pH 7.0 was less favourable to accommodate
toxin as a chiral conformer.
Probing the binding site of Creatinine on HSA by Ligand
Displacement experiments
Further spectroscopic experiments were undertaken to obtain
information on the potential location of the HSA binding site of
CTN. Albumin possesses two main drug binding sites, site I and II,
which are located in hydrophobic cavities of subdomains IIA and
Figure 5. Fluorescence quenching of HSA with creatinine at different ligand/protein ratios. Stern-Volmer (A&C) and modified Stern-
Volmer (B&D) plots of N (A&B) and B (C&D) isomeric conformations of HSA with uremic toxin creatinine. Each data point was the mean of 3
independent observations (S.D. ranging 0.03–0.4%). The Protein was excited at 280 (¤) and 295 nm (e).
doi:10.1371/journal.pone.0017230.g005
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same binding site as creatinine, amplitudes of the induced cotton
effects should decrease due to competition. Therefore, CD
displacement experiments were performed using four marker
ligands warfarin and phenylbutazone for site I whereas ibuprofen
and the benzodiazepine agent diazepam for site II. Monitoring the
induced CD spectrum of creatinine during the titration showed a
rapid extinction of extrinsic CD activity for both isomers of HSA
but this extinction was found to be more steep at pH 9.0 (Figure 7).
Especially the site I markers, phenylbutazone followed by warfarin
were found to be responsible for reducing the CD signal of the
protein-toxin complex to almost zero. Thereby, suggesting the
direct competitive interaction between site I markers and
creatinine for the binding site I. Notably, nearly complete
extinction of the CD signal was achieved for both isomeric forms
of HSA suggesting that the binding site was not affected by the
protonation of albumin molecules.
Molecular docking study of uremic toxin creatinine–HSA
interaction
The locations of uremic toxin creatinine in the active sites (site
I and site II) of HSA was explored by conducting docking
simulations using GOLD [29] as presented in Figure 8 and 9.
The principal regions of ligand binding to HSA were located in
hydrophobic cavities in subdomains IIA and IIIA, which are
consistent with site I and site II, respectively [20]. The
creatinine, site I markers (phenylbutazone and warfarin) were
docked to HSA and the results have been shown in Table 4 and
5. The Gold Fitness Score, measure of binding affinity was found
to be low for CTN at both of the sites when compared to
respective markers used in this study; however specificity was
higher for site I as evident from the presence of hydrogen bond
and hydrophobic interactions. The spectroscopic experimental
Figure 6. Induced circular dichroism and UV/vis spectra of
creatinine-HSA complex. Representative CD and UV spectra
obtained following the titration of the buffer solution of HSA with
creatinine at (A) pH 7.0 and (B) pH 9.0. Spectral contributions of the
protein alone were subtracted from the spectra of the toxin–protein
mixture ([HSA] =100 mM, T=25uC). Demax values calculated on the basis
of the total ligand concentrations are displayed at the different molar
ratios (L/P). Arrows denote increasing concentration of uremic toxin
CTN.
doi:10.1371/journal.pone.0017230.g006
Figure 7. Displacing effect of HSA site specific markers on the
ICD signal of creatinine-HSA complex. Results of CD displacement
experiments performed with warfarin, phenylbutazone, ibuprofen and
diazepam on HSA-CTN complex at (A) pH 7.0 and (B) pH 9.0 (l=1 cm,
T=25uC). Displacers were added as ml aliquots of stock solutions.
Positive induced CD values measured at 278 nm are plotted against
displacer/creatinine molar ratios (for further details see Materials and
methods).
doi:10.1371/journal.pone.0017230.g007
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PLoS ONE | www.plosone.org 9 February 2011 | Volume 6 | Issue 2 | e17230Figure 8. Molecular docking of HSA complexed with site I specific markers. (A) Molecular surface representations of HSA showing site I
specific markers [warfarin (limegreen); phenylbutazone (yellow)] and the toxin CTN (red) at binding site I. (B) One hydrogen bond (as highlighted by
the yellow dashed line) was formed between CTN and Arg257 of HSA. The hydrogen bond length was represented in yellow colour (C) Other site I
amino acid residues of HSA interacting with CTN within 5 A ˚ distance.
doi:10.1371/journal.pone.0017230.g008
Figure 9. Molecular docking of HSA complexed with site II specific markers. (A) Molecular surface representations of HSA showing site II
specific markers [ibuprofen (light orange); diazepam (magenta)] and the toxin CTN (red) at binding site II. (B) The toxin molecule forming repulsive
interaction (white colour) with Phe488 of HSA (as highlighted by the white dashed line). (C) Other site II amino acid residues of HSA interacting with
CTN within 5 A ˚ distance.
doi:10.1371/journal.pone.0017230.g009
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high and low affinity binding sites of toxin on plasma protein are
located within the binding pocket of subdomain IIA and IIIA.
The creatinine binds deep inside the cavity at site I (Figure 8)
whereas in site II (Figure 9), it binds at peripheral side of the
cavity. The inside wall of the pocket was lined by hydrophobic
side chains whereas the entrance to the pocket was surrounded
by several non-polar residues (Leu238, Val241, Ala258, Leu260,
Ala261, Ile264, Ile290, Ala291); one polar (Ser287) and few
charged residues (His242, Arg257) in the proximity distance of
5A ˚ of the bound toxin (Figure 8, Table 4). Although the
involvement of non polar residues makes the interactions to be
Table 5. Change in Accessible surface area and binding interactions of the site II amino acid residues of HSA with uremic toxin
creatinine.
Ligands
Amino acid
residue DASA (A ˚ 2) Location Electrostatic Interaction
Number of other
interacting
residues (5 A ˚)
GOLD
Fitness score X-score
Creatinine Tyr 411
Phe 488
Glu 489
35.66
26.38
10.27
IIa-h2
IIIa-h6
IIIa-h4
Repulsive force
C=O…N
3
Phe488(2.62 A ˚)
7 29.14 25.55
Diazepam Leu 453
Asn 391
Ile 388
Leu 387
Leu 430
Arg 485
Ala 449
31.13
28.27
23.93
18.46
16.62
14.67
13.73
IIIa-h4
IIIa-h1
IIIa-h1
IIIa-h1
IIIa-h3
IIIa-h6
IIIa-h4
15 41.10 28.43
Ibuprofen Leu 453
Val 485
Asn 391
Leu 387
Ile 388
Pro 384
Glu 450
28.22
27.55
21.82
19.4
16.85
10.79
10.79
IIIa-h4
IIIa-h6
IIIa-h1
IIIa-h1
IIIa-h1
IIIa-h1
IIIa-h4
13 42.74 27.29
doi:10.1371/journal.pone.0017230.t005
Table 4. Change in Accessible surface area and binding interactions of the site I amino acid residues of HSA with uremic toxin
creatinine.
Ligands
Amino
acidresidue
DASA
(A ˚ 2) Location
Electrostatic
Interaction
Number of other
interacting
residues (5 A ˚)
GOLD
Fitness score X-score
Creatinine Arg257
Leu238
Ala291
Ser287
Leu260
17.96
17.08
16.05
12.02
10.58
IIa-h4
IIa-h6
IIa-h3
IIa-h6
IIa-h4
Hydrogen bond
C=O…H
2N
Arg257(2.85 A ˚)
10 28.16 25.68
Phenyl-butazone Ala 291
Leu238
Leu242
Trp214
Arg257
Ile264
Arg222
Leu219
Ser287
Ile290
Leu260
42.9
41.79
33.66
22.61
18.95
13.04
12.82
12.69
12.02
11.48
11.17
IIa-h6
IIa-h3
IIa-h3
IIa-h2
IIa-h4
IIa-h4
IIa-h2
IIa-h2
IIa-h6
IIa-h6
IIa-h4
15 47.82 28.49
Warfarin Leu238
Ala291
Leu242
Trp214
Arg257
Arg222
Leu219
Ser287
Ile290
Phe211
Leu260
39.03
38.6
35.6
28.93
16.4
14.05
12.25
12.02
11.48
11.26
10.72
IIa-h3
IIa-h6
IIa-h3
IIa-h2
IIa-h4
IIa-h2
IIa-h2
IIa-h6
IIa-h6
IIa-h2
IIa-h4
15 41.62 28.05
doi:10.1371/journal.pone.0017230.t004
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bond between carbonyl oxygen atom of Arg257 and N2 atom of
creatinine (2.85 A ˚, 124.36u), makes the electrostatic interaction
as the primary binding force responsible for the retention of
toxin in the plasma. The hydrogen bond residue of site I (Arg
257) was part of helix 4 and 6 of subdomain IIA (represented as
IIa-h4 & IIa-h6, Table 4). While at site II, the complex was
stabilized by hydrophobic interactions without involvement of
any hydrogen bond. Additionally, electrostatic repulsive force
b e t w e e no x y g e na t o mo fP h e 4 8 8w i t hN 3 of creatinine (2.62 A ˚)
destabilizes the complex (Figure 9, Table 5). To further identify
the residues taking part in the interaction, we have calculated the
accessible surface area (ASA) of the amino acid residues. The
changes in ASA of the interacting residues are presented in
Table 4 and 5.
Discussion
The HSA solutions used in our preparations was approximately
equivalent to that present in the blood i.e. 500 mM. Although under
this condition the HSA solution was very concentrated but we have
checked for the possibility of aggregation formation while
performing the experiments. No evidence was found for aggrega-
tion/turbidity in solution provided by the Rayleigh light scattering
(RLS) experiments (Figure S1) in scattering intensity after 1 hr. By
RLS time dependent in solutions increase was in a concentration
dependent manner. It appears that no aggregation was been
reported when concentration was increased from 150 mM (10 mg/
ml) to higher concentrations ,500 mM (33 mg/ml).
The melting thermograms for HSA were shown in Figure 1
attributes to an excessive load of hydrophobic uremic toxin bound
to the albumin molecule. The uremic plasma under physiological
conditions have a different shape with a shift to the right at higher
temperatures and increase in the height above baseline which was
also reflected in the values of the melting enthalpy (Table 1). This
was attributed to a higher thermoresistance of the albumin
component, most probably because of the binding of uremic toxin
to HSA. An increase in the number of intramolecular bonds
increases the thermal stability of the protein molecule and more
pronounced at pH 9.0. Therefore, binding of toxin increases the
cooperativity of the melting process and depends on its affinity for
the albumin molecule. Comparison of thermodynamic parameters
with the spectroscopic method (Table 2) shows that the two
measurements yield similar ‘n’ values at both pHs. Because DH
was much less than 60 Kcal/mol [39], the CTN-HSA interaction
was non-covalent: it involves H-bonds, ion-pair attraction,
hydrophobic interaction, and van der waals forces. It can be
observed that, at physiological pH, the binding affinity decreases.
This was reflected in the high negative values of enthalpy of
binding, DHITC, and in a larger affinity binding constant, KITC
(Table 2). Our finding that the secondary structure of serum
albumin from conditions similar to uremic patients remains intact
was consistent with circular dichroism data on the uHSA
conformation in solution as determined previously [38]. Likewise,
modification of IR spectra indicating alterations in structure of
uHSA agrees well with published data about the physicochemical
peculiarities of albumin in chronic uremia. We do not observe any
significant changes in the secondary environment of protein on
complexation with the toxin. On the other hand, number of
binding sites ‘n’ remained almost unaffected. This indicates
increased stability of B-CTN complex. Since under increased
Ca
2+ concentration in the blood plasma, the B isomer predom-
inates, it is suggested that N-B conformational changes have
physiological significance [20,18].
The question arises which binding sites on the albumin
molecule were usually affected by creatinine? Data for the binding
ability of albumin before and after its loading with uremic toxin
with marker ligand specific for sites I and II were represented by
displacement experiments as shown in Figure 7. The site I markers
at pH 7 and 9 reduces the induced CD signal to almost zero. The
association constant of phenylbutazone was Ka 7610
5 M
21,n=1
and warfarin was Ka=3.3610
5 M
21, n=1 [20] and that for CTN
(after exciting the protein at 280 nm) was Ka=1.4610
5 M
21,
n<1 (Table 2) the site I markers can displace CTN from its
binding site on albumin. The association constant for diazepam
(Ka=3.8610
5 M
21, n=1) and ibuprofen (Ka=2.7610
5 M
21,
n=1) [20] was higher than that for CTN and lower than that for
site I markers. Site II markers were, therefore, likely to weak
inhibitors of the binding of CTN. Thus, fluorescence quenching
and induced CD spectrums were utilized to achieve three goals (i)
calculating the association constant (Ka) (ii) determining the
dependence of toxin binding on albumin conformation and (iii)
probing the location of uremic toxin binding site on HSA.
Furthermore, CTN possesses two pKa values of 4.88 for
protonation [40] and 12.7–13.4 for deprotonation of the exocyclic
amino group. This suggests that CTN predominantly occurs in
aqueous solution and in blood plasma at pH 7.4 in neutral form.
In aqueous solution it exists in the form of a tautomer, its acido–
basic equilibrium has been shown in Figure 10. When analyzing
the accessible surface area we found main involvement of arginine
residues in the toxin complexation with albumin (Table 4). This
change seemed to be caused by His residues because most of the
pKa values of His residues are within this pH region i.e. 6.4. Thus,
during alkalization of HSA, the affinity of CTN increases. On the
onset of pH 9.0, the Arg residues involved in binding protonate
(pKa of Arg =9.04 (NH
3+) and 12.04 (side chain)), and then may
Figure 10. The acidic-basic equilibrium of creatinine. In aqueous
solution creatinine exists in the form of a tautomer.
doi:10.1371/journal.pone.0017230.g010
Figure 11. Common amino acid residues between creatinine
and HSA. The shaded area depicts the common amino acid residues
spanning uremic toxin creatinine and specific drug site I markers of
HSA.
doi:10.1371/journal.pone.0017230.g011
Elimination of Creatinine from Blood Plasma
PLoS ONE | www.plosone.org 12 February 2011 | Volume 6 | Issue 2 | e17230interact favorably with the toxin. Whilst at pH 7.0, deprotonation
weakens the interaction with the cation.
What actually happens under in vivo conditions during chronic
renal failure (CRF) when urine eliminates from the body? The
glomerulus is a selective filtration membrane. The filtration barrier
of body composed of three layers that allow for the filtration of
solutes (eg. blood urea nitrogen, creatinine, electrolytes) and water,
but prevent the loss of blood components and plasma proteins.
Two mechanisms act to prevent albumin from being lost from the
body by filtration through the glomerular membrane. The first
relates to the glomerular membrane pore size, which is small
compared to the size and shape of albumin. The second
mechanism involves the negatively charged sialo-protein-rich
electrical charge on the surface of endothelial cells covering the
inner surface of the basement membrane. Since albumin has a net
negative charge, it is electrostatically repulsed by the glomerular
membrane. As a result, it has been estimated that only about 2 g of
albumin was filtered each day across the glomerular capillary wall.
Creatinine, on the other hand, lacks electrical charges at
physiological pH and hence is able to escape across the muscle
cell membrane. It is found that highly alkaline urine occurs in
CRF. Our in vitro results could be correlated with this fact i.e.
under alkaline conditions interaction of toxins enhances due to
increased affinity with HSA. Thus, elimination of toxin would be
more feasible at physiological pH.
Furthermore, the major changes in ASA occur for the residues
(role in binding) belonging to the hydrophobic pocket of site I.
These residues were overlapping to those of site I markers (Table 4)
thereby again supporting the results of site I displacement
(Figure 11). Whereas, the residues involved in binding of CTN
to site II (Table 5) were non overlapping to those of respective
markers, moreover the no. of such residues was less than that for
site I.
Curry et al. have determined the crystal structure of HSA
complexed with five molecules of fatty acid at 2.5 A ˚ resolution
[20]. Arg 257 was found to interact with myristate bound to
subdomain IIA. Similar interaction we observed with HSA-CTN
complexation. It was noteworthy that the single tryptophan
residue of HSA (Trp 214) was not in the immediate environment
of the docked toxin molecule as proved by our spectroscopic
results and was further confirmed by computational mapping
approaches. Guanidino compounds are generated in vivo as a result
of protein and amino acid metabolism. In general the GCs acquire
the guanidino group from arginine, with subsequent methylation
to creatine and further metabolization to creatinine [41]. In
patients with renal impairment, several-fold increases in specific
guanidino compounds were observed due to the impaired renal
function and altered metabolism [6]. Most drugs are bound to
serum proteins to a various degree. Only unbound or free drug is
pharmacologically active. There is equilibrium between bound
and free drugs, and concentration of free drug can be predicted
from total drug concentration. However, under uremic conditions
this equilibrium is disturbed and the measured free drug
concentration can be significantly higher than expected from total
drug concentrations, especially for strongly protein-bound drugs.
In such case a patient may experience drug toxicity (Figure 12).
Furthermore, creatinine is removed by hemodialytic strategies
[42] but under diseased states uremic compounds of low molecular
mass can displace strongly albumin-bound drugs from binding
sites responsible for the binding defect of various drugs in uremic
sera. To account for the mechanisms that govern such specificity
in inhibitory potency, we carefully examined the relationship
Figure 12. Correlation between uremic toxicity and impaired drug binding. Mechanism showing possible cascade displacement model in
uremic toxin– drug system depicts allosteric effect of toxin when binding to site I and site II. Red colour: CTN binding to its high-affinity site, site Ia s
shown by solid arrows; blue colour: CTN binding to its low-affinity site, site II as shown by dashed arrows. Hemodialytic reaction occurring within the
blood plasma has been shown in red box.
doi:10.1371/journal.pone.0017230.g012
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In summary, accumulation of creatinine in patients with renal
failure appears to account for a substantial portion of the impaired
serum protein binding of drug especially at site I. Consequently,
interactions of toxin and drug with respect to serum protein
binding and renal excretion may increase the free fraction of drug
in serum of patients with renal insufficiency [43]. These findings
lend further support to the hypothesis that a retained ligand(s) was
responsible for impaired plasma binding associated with uremia
and suggests a role for CTN known to accumulate in renal failure.
Renal failure not only alters the renal elimination but also the
non renal elimination disposition of drugs that are extensively
metabolized by the liver. Clearance of CTN from the blood
depends on intramuscular CTN levels, hormone levels, muscle
mass, and kidney function/glomerular filtration rate. Creatinine is
representative for small uremic toxins, important in clinical
analytic domain for it is used as a probe to evidence renal failure
or muscular dysfunction. Consequently, accumulation of uremic
toxin and slight increase of pH may cause increase of the free
fraction of drug due to interaction of toxin in patients with renal
failure. Thus, accumulation of uremic toxin in body can be due to
conformational change caused by neutral to basic transition which
in turn may affect the site–site interactions between domain IIA
and domain IIIA such that site interactions between domains will
disappear. The findings obtained here will provide useful
information for elucidating the complicated mechanism of drug
and toxin disposition in renal disease state. This is the current
interest of the pharmaceutical companies. This is extremely
important for various diseases such as muscular dystrophy and
diabetes. Most of the future research and advances well be spun off
of these clinical studies.
Supporting Information
Figure S1 Rayleigh light scattering of HSA. The Rayleigh
light scattering of HSA at pH 7.0 measured on Hitachi (F-4500)
fluorescence spectrophotometer. The excitation and emission
wavelengths were set at 350 nm. Both slit widths were set at
10 nm and emission was scanned at time intervals ranging from 0
to 3600 sec (1 hr) by maintaining the temperature at 25uC.
(TIF)
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